D3D3

D3D3 is a D-enantiomeric peptide developed for the treatment of Alzheimer's disease. It is a tandem-repeat derivative of the D3 peptide, consisting of two D3 sequences linked together (rprtrlhthrnrrprtrlhthrnr). D3D3 is designed to specifically bind to and eliminate toxic amyloid-beta (Aβ) oligomers, which are considered the primary synaptotoxic species in Alzheimer's pathology. By stabilizing Aβ in a non-toxic monomeric state or converting existing oligomers into non-toxic aggregates, D3D3 aims to prevent the cognitive decline associated with amyloid accumulation. Preclinical studies have demonstrated that oral administration of D3D3 significantly improves cognitive performance in transgenic mouse models of Alzheimer's disease, such as APP/PS1 and APPSL mice, without necessarily reducing the overall plaque load, suggesting a targeted mechanism against soluble oligomeric species.